论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Guo XN, Zhu XS, Liu DK, Gong YB, Sun J, Dong CX
Received 21 March 2017
Accepted for publication 12 June 2017
Published 18 September 2017 Volume 2017:12 Pages 6923—6936
DOI https://doi.org/10.2147/IJN.S137634
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Farooq Shiekh
Peer reviewer comments 3
Editor who approved publication: Dr Lei Yang
Purpose: To reduce the adverse effects and high frequency of administration
of propranolol to treat infantile hemangioma, we first utilized
propranolol-loaded liposomes-in-microsphere (PLIM) as a novel topical release
system to realize sustained release of propranolol.
Methods: PLIM was developed from encapsulating
propranolol-loaded liposomes (PLs) in microspheres made of
poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic
acid) copolymers (PLGA-PEG-PLGA). The release profile of propranolol from PLIM
was evaluated, and its biological activity was investigated in vitro using
proliferation assays on hemangioma stem cells (HemSCs). Tumor inhibition was
studied in nude mice bearing human subcutaneous infantile hemangioma.
Results: The microspheres were of desired particle size
(~77.8 µm) and drug encapsulation efficiency (~23.9%) and achieved sustained
drug release for 40 days. PLIM exerted efficient inhibition of the
proliferation of HemSCs and significantly reduced the expression of two angiogenesis
factors (vascular endothelial growth factor-A [VEGF-A] and basic fibroblast
growth factor [bFGF]) in HemSCs. Notably, the therapeutic effect of PLIM in
hemangioma was superior to that of propranolol and PL in vivo, as reflected by
significantly reduced hemangioma volume, weight, and microvessel density. The
mean hemangioma weight of the PLIM-treated group was significantly lower than
that of other groups (saline =0.28 g, propranolol =0.21 g, PL =0.13 g, PLIM
=0.03 g; PLIM vs saline: P <0.001, PLIM vs
propranolol: P <0.001, PLIM vs PL: P <0.001). The mean microvessel
density of the PLIM-treated group was significantly lower than that of other
groups (saline =40 vessels/mm2, propranolol =31
vessels/mm2, PL =25 vessels/mm2,
PLIM =11 vessels/mm2; PLIM vs saline: P <0.001, PLIM vs propranolol: P <0.01, PLIM vs PL: P <0.05).
Conclusion: Our findings show that PLIM is a very promising
approach to locally and efficiently deliver propranolol to the hemangioma site
leading to a significant inhibition of infantile hemangioma.
Keywords: propranolol,
liposomes, microsphere, controlled release, hemangioma